Rockwell Medical, Inc. (NASDAQ:RMTI - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.34 and traded as high as $3.52. Rockwell Medical shares last traded at $3.48, with a volume of 165,938 shares.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and issued a $9.00 target price on shares of Rockwell Medical in a research note on Wednesday, September 11th.
Check Out Our Latest Research Report on Rockwell Medical
Rockwell Medical Trading Down 0.4 %
The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 2.00. The company's fifty day moving average is $3.43 and its two-hundred day moving average is $2.36. The company has a market cap of $107.36 million, a price-to-earnings ratio of -20.35 and a beta of 1.48.
Rockwell Medical (NASDAQ:RMTI - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $25.83 million during the quarter, compared to analyst estimates of $23.01 million. Rockwell Medical had a negative return on equity of 6.96% and a negative net margin of 5.06%. During the same quarter last year, the business posted ($0.18) EPS. On average, research analysts anticipate that Rockwell Medical, Inc. will post -0.03 EPS for the current year.
Institutional Investors Weigh In On Rockwell Medical
A number of institutional investors have recently modified their holdings of RMTI. Armistice Capital LLC lifted its holdings in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company's stock valued at $5,670,000 after purchasing an additional 592,000 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Rockwell Medical by 877.1% during the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company's stock valued at $181,000 after acquiring an additional 92,189 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company's stock worth $1,856,000 after purchasing an additional 43,302 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors and hedge funds.
Rockwell Medical Company Profile
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
See Also
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
